Review Article
Emerging Pharmacotherapies for Diabetic Macular Edema
Table 2
Selected clinical trials of VEGF antagonists in treatment of diabetic macular edema.
| Agent (no. patients) | Main outcomes | Reference |
| Pegaptanib (260) | More favorable outcomes versus sham at 2 years | [43] | Bevacizumab | | | DRCR phase II (121) | More favorable outcomes versus photocoagulation at 3 weeks | [45] | BOLT study (80) | More favorable outcomes versus photocoagulation at 1 year | [46] | Ranibizumab | | | READ-2 study (126) | More favorable outcomes versus photocoagulation at 2 years | [53] | DRCR protocol I (691) | Ranibizumab with photocoagulation more favorable than photocoagulation alone at 2 years | [54] | RESTORE study (345) | Ranibizumab with or without photocoagulation more favorable than photocoagulation alone at 1 year | [57] | RISE/RIDE studies (377) | More favorable outcomes versus sham at 2 years | [59] | RESOLVE study (151) | More favorable outcomes versus sham at 1 year | [60] | Aflibercept | | | DA VINCI study (219) | More favorable outcomes versus photocoagulation at 1 year | [66] |
|
|